Department of Pulmonary Medicine, AIIMS Patna, 801505, India.
Department of Pulmonary Medicine, AIIMS Patna, 801505, India.
Indian J Tuberc. 2021 Jul;68(3):330-333. doi: 10.1016/j.ijtb.2020.11.003. Epub 2020 Nov 10.
After the COVID-19 outbreak, increasing number of patients worldwide who have survived COVID-19 continue to battle the symptoms of the illness, long after they have been clinically tested negative for the disease. As we battle through this pandemic, the challenging part is to manage COVID-19 sequelae which may vary from fatigue and body aches to lung fibrosis. This review addresses underlying mechanism, risk factors, course of disease and treatment option for post covid pulmonary fibrosis. Elderly patient who require ICU care and mechanical ventilation are at the highest risk to develop lung fibrosis. Currently, no fully proven options are available for the treatment of post inflammatory COVID 19 pulmonary fibrosis.
在 COVID-19 爆发后，全球越来越多的 COVID-19 幸存者在临床检测呈阴性后仍继续与疾病的症状作斗争。在我们与这场大流行作斗争的过程中，具有挑战性的部分是管理 COVID-19 后遗症，这些后遗症可能从疲劳和身体疼痛到肺纤维化不等。这篇综述介绍了新冠后肺纤维化的潜在机制、危险因素、疾病过程和治疗选择。需要 ICU 护理和机械通气的老年患者发生肺纤维化的风险最高。目前，尚无经充分证实的方法可用于治疗 COVID-19 后炎症性肺纤维化。
